The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.
The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.
复制标题
DOI：
10.3390/cancers15225434
复制
发表时间：
2023-11-16
期刊：
影响因子：
5.2
通讯作者：
Kalofonou, Melpomeni
中科院分区：
文献类型：
--
作者：
Alexandrou, George;Mantikas, Katerina-Theresa;Allsopp, Rebecca;Yapeter, Calista Adele;Jahin, Myesha;Melnick, Taryn;Ali, Simak;Coombes, R. Charles;Toumazou, Christofer;Shaw, Jacqueline;Kalofonou, Melpomeni
本综述旨在强调以各种方式使用循环肿瘤 DNA 和循环肿瘤细胞来护理癌症患者。提到了目前使用这些生物标记物所采用的不同技术并与其他技术进行了对比，同时还讨论了它们的局限性，例如可负担性和可扩展性。此次审查还旨在为液体活检领域的新兴技术带来光明，这些技术尚未获得监管委员会的批准，但在开发时考虑了可负担性和可扩展性的概念。人们发现，这些技术因素对于提供尖端的诊断和监测方案非常重要，因为它们可以为所有人带来个性化治疗和患者分层。尽管诊断和治疗取得了许多进展，但癌症仍然是全世界死亡的主要原因。精准医学一直是关注的关键领域，研究提供了见解和进展，通过更好的患者分层治疗和更精确的诊断技术来帮助降低癌症死亡率。然而，获得癌症护理的机会不平等仍然是一个全球性问题，许多患者获得诊断测试和治疗方案的机会有限。无创液体活检 (LB) 技术可以确定外周样本中肿瘤特异性分子的变化。这使得临床医生能够推断 DNA 或细胞水平的知识，从而可用于筛查癌症风险高的个体、个性化治疗、监测治疗反应并及早检测转移。随着对癌症病理学的科学认识不断加深，利用循环肿瘤 DNA (ctDNA) 和循环肿瘤细胞 (CTC) 的 LB 技术在研究过程中不断发展。这些技术将肿瘤特异性标记物纳入分子测试平台。为了在更广泛的范围内实现临床转化和最大程度地提高患者利益，需要优先考虑 LB 检测的准确性、可及性和可负担性，并与当前使用的金标准方法进行比较。在这篇综述中，我们重点介绍了 LB 诊断技术的范围，并通过当前技术的预期演变以及新兴技术和新技术的整合来讨论 LB 的未来前景。这可能会让更具成本效益的癌症治疗模式得到广泛采用。
This review aims to highlight the usage of circulating tumour DNA and circulating tumour cells in various manners for the care of cancer patients. The different technologies that are currently employed using these biomarkers are mentioned and contrasted with another whilst also discussing their limitations such as affordability and scalability. The review also aims to bring light to newer emerging technologies in the space of liquid biopsy that have yet to be approved by a regulatory board but have been developed with the notion of affordability and scalability in mind. These factors of technology are found to be important in order to provide cutting edge diagnostic and monitoring regimes as they can lead to personalised treatments and patient stratification for all. Cancer remains a leading cause of death worldwide, despite many advances in diagnosis and treatment. Precision medicine has been a key area of focus, with research providing insights and progress in helping to lower cancer mortality through better patient stratification for therapies and more precise diagnostic techniques. However, unequal access to cancer care is still a global concern, with many patients having limited access to diagnostic tests and treatment regimens. Noninvasive liquid biopsy (LB) technology can determine tumour-specific molecular alterations in peripheral samples. This allows clinicians to infer knowledge at a DNA or cellular level, which can be used to screen individuals with high cancer risk, personalize treatments, monitor treatment response, and detect metastasis early. As scientific understanding of cancer pathology increases, LB technologies that utilize circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) have evolved over the course of research. These technologies incorporate tumour-specific markers into molecular testing platforms. For clinical translation and maximum patient benefit at a wider scale, the accuracy, accessibility, and affordability of LB tests need to be prioritized and compared with gold standard methodologies in current use. In this review, we highlight the range of technologies in LB diagnostics and discuss the future prospects of LB through the anticipated evolution of current technologies and the integration of emerging and novel ones. This could potentially allow a more cost-effective model of cancer care to be widely adopted.
登录
查看更多内容
影响因子：
4.6
作者：
Fachin F;Spuhler P;Martel-Foley JM;Edd JF;Barber TA;Walsh J;Karabacak M;Pai V;Yu M;Smith K;Hwang H;Yang J;Shah S;Yarmush R;Sequist LV;Stott SL;Maheswaran S;Haber DA;Kapur R;Toner M
通讯作者：
Toner M
影响因子：
3.8
作者：
Deng G;Krishnakumar S;Powell AA;Zhang H;Mindrinos MN;Telli ML;Davis RW;Jeffrey SS
通讯作者：
Jeffrey SS
DOI：
10.1007/978-3-319-42044-8_34
发表时间：
2016-01-01
期刊：
CIRCULATING NUCLEIC ACIDS IN SERUM AND PLASMA - CNAPS IX
影响因子：
--
作者：
Fredebohm, Johannes;Mehnert, Daniel H.;Diehl, Frank
通讯作者：
Diehl, Frank
影响因子：
12.4
作者：
Chen L;Bode AM;Dong Z
通讯作者：
Dong Z
DOI：
10.1126/science.aar3247
发表时间：
2018-02-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Cohen JD;Li L;Wang Y;Thoburn C;Afsari B;Danilova L;Douville C;Javed AA;Wong F;Mattox A;Hruban RH;Wolfgang CL;Goggins MG;Dal Molin M;Wang TL;Roden R;Klein AP;Ptak J;Dobbyn L;Schaefer J;Silliman N;Popoli M;Vogelstein JT;Browne JD;Schoen RE;Brand RE;Tie J;Gibbs P;Wong HL;Mansfield AS;Jen J;Hanash SM;Falconi M;Allen PJ;Zhou S;Bettegowda C;Diaz LA Jr;Tomasetti C;Kinzler KW;Vogelstein B;Lennon AM;Papadopoulos N
通讯作者：
Papadopoulos N